Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Acalabrutinib: First Global Approval.

Literature DB >> 29209955

Acalabrutinib: First Global Approval.

Abstract

Acerta Pharma is developing the Bruton's tyrosine kinase inhibitor acalabrutinib (Calquence®) for the treatment of various haematological and solid malignancies. The drug has received accelerated approval from the US FDA for the treatment of mantle cell lymphoma based on the results of a phase II study, and phase III trials in mantle cell lymphoma and chronic lymphocytic leukaemia are currently underway. This article summarizes the milestones in the development of acalabrutinib leading to this first approval for mantle cell lymphoma.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2018 PMID： 29209955 DOI： 10.1007/s40265-017-0852-8

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

3 in total

1. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.

Authors: Sarah E M Herman; Arnau Montraveta; Carsten U Niemann; Helena Mora-Jensen; Michael Gulrajani; Fanny Krantz; Rose Mantel; Lisa L Smith; Fabienne McClanahan; Bonnie K Harrington; Dolors Colomer; Todd Covey; John C Byrd; Raquel Izumi; Allard Kaptein; Roger Ulrich; Amy J Johnson; Brian J Lannutti; Adrian Wiestner; Jennifer A Woyach
Journal: Clin Cancer Res Date: 2016-11-30 Impact factor: 12.531

2. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

Authors: John C Byrd; Bonnie Harrington; Susan O'Brien; Jeffrey A Jones; Anna Schuh; Steve Devereux; Jorge Chaves; William G Wierda; Farrukh T Awan; Jennifer R Brown; Peter Hillmen; Deborah M Stephens; Paolo Ghia; Jacqueline C Barrientos; John M Pagel; Jennifer Woyach; Dave Johnson; Jane Huang; Xiaolin Wang; Allard Kaptein; Brian J Lannutti; Todd Covey; Maria Fardis; Jesse McGreivy; Ahmed Hamdy; Wayne Rothbaum; Raquel Izumi; Thomas G Diacovo; Amy J Johnson; Richard R Furman
Journal: N Engl J Med Date: 2015-12-07 Impact factor: 91.245

3. Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.

Authors: Bonnie K Harrington; Heather L Gardner; Raquel Izumi; Ahmed Hamdy; Wayne Rothbaum; Kevin R Coombes; Todd Covey; Allard Kaptein; Michael Gulrajani; Bart Van Lith; Cecile Krejsa; Christopher C Coss; Duncan S Russell; Xiaoli Zhang; Bridget K Urie; Cheryl A London; John C Byrd; Amy J Johnson; William C Kisseberth
Journal: PLoS One Date: 2016-07-19 Impact factor: 3.240

3 in total

12 in total

1. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.

Authors: Aditya Sharma; B K Thelma
Journal: J Mol Model Date: 2019-06-06 Impact factor: 1.810

2. Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects.

Authors: H Yesid Estupiñán; Thibault Bouderlique; Chenfei He; Anna Berglöf; Dhanu Gupta; Osama Saher; Miguel Ángel Daza Cruz; Lucia Peña-Perez; Liang Yu; Rula Zain; Mikael C I Karlsson; Robert Månsson; C I Edvard Smith
Journal: Blood Adv Date: 2020-06-09

3. Abivertinib inhibits megakaryocyte differentiation and platelet biogenesis.

Authors: Jiansong Huang; Xin Huang; Yang Li; Xia Li; Jinghan Wang; Fenglin Li; Xiao Yan; Huanping Wang; Yungui Wang; Xiangjie Lin; Jifang Tu; Daqiang He; Wenle Ye; Min Yang; Jie Jin
Journal: Front Med Date: 2021-11-18 Impact factor: 9.927

4. Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.

Authors: Caroline E O'Riordan; Gareth S D Purvis; Debora Collotta; Fausto Chiazza; Bianka Wissuwa; Sura Al Zoubi; Lara Stiehler; Lukas Martin; Sina M Coldewey; Massimo Collino; Christoph Thiemermann
Journal: Front Immunol Date: 2019-09-06 Impact factor: 7.561

5. X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure.

Authors: Caroline E O'Riordan; Gareth S D Purvis; Debora Collotta; Nadine Krieg; Bianka Wissuwa; Madeeha H Sheikh; Gustavo Ferreira Alves; Shireen Mohammad; Lauren A Callender; Sina M Coldewey; Massimo Collino; David R Greaves; Christoph Thiemermann
Journal: Front Immunol Date: 2020-10-07 Impact factor: 7.561

Review 6. B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders.

Authors: Jan Traub; Leila Husseini; Martin S Weber
Journal: Pharmaceuticals (Basel) Date: 2021-01-06

Review 7. Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia.

Authors: Kalpana K Bhanumathy; Amrutha Balagopal; Frederick S Vizeacoumar; Franco J Vizeacoumar; Andrew Freywald; Vincenzo Giambra
Journal: Cancers (Basel) Date: 2021-01-07 Impact factor: 6.639

Review 8. FDA-Approved Drugs for Hematological Malignancies-The Last Decade Review.

Authors: Aleksandra Sochacka-Ćwikła; Marcin Mączyński; Andrzej Regiec
Journal: Cancers (Basel) Date: 2021-12-24 Impact factor: 6.639

9. A novel LC-MS/MS method for simultaneous estimation of acalabrutinib and its active metabolite acalabrutinib M₂₇ in human plasma and application to a human pharmacokinetic study.

Authors: Venkat Rao Valluri; Naresh Kumar Katari; Chirag Khatri; Pankaj Kasar; Srinivasa Rao Polagani; Sreekanth Babu Jonnalagadda
Journal: RSC Adv Date: 2022-02-25 Impact factor: 3.361

Review 10. Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.

Authors: Maude Sestier; Christopher Hillis; Graeme Fraser; Darryl Leong
Journal: Curr Oncol Rep Date: 2021-08-03 Impact factor: 5.075